On November 10, GenScript ProBio and specialized CAR-T therapy firm Curocell signed a strategic partnership MOU for the production of viral vectors necessary for the development of next generation of CAR-T therapy, marking another significant step in their ongoing collaboration. This partnership will broaden the strategic cooperation between the two companies to encompass the entire project, including the development, production, and clinical trials of viral vectors for CAR-T therapy research and development. Viral vectors are vehicles for drug delivery that utilize viruses to transport genetic material to the cellular interior.

The demand for viral vectors is rapidly increasing due to the recent growth of the gene therapy market, which uses CAR-T therapy as its main active ingredient. However, it has been noted that a shortage of GMP facilities producing viral vectors is causing delays in the development of gene therapies, including CAR-T therapy.